Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12698427 | 0.85 | L3MBTL1 (0.47) | L3MBTL1GLAPTGDR2ALDH1A1HCRTR1 | |
| SCHEMBL2292901 | 0.84 | PTGDR2 (0.46) | PTGDR2ALDH1A1HPGDPOLBTSHR | |
| SCHEMBL16713296 | 0.84 | L3MBTL1 (0.46) | L3MBTL1GLAPTGDR2ALDH1A1HCRTR1 | |
| SCHEMBL670658 | 0.81 | FFAR1 (0.52) | L3MBTL1PTGDR2ALDH1A1TDP1POLB | |
| SCHEMBL9355648 | 0.77 | MAPT (0.50) | L3MBTL1GLAPTGDR2ALDH1A1CYP2C19 | |
| SCHEMBL5243360 | 0.77 | ALDH1A1 (0.53) | L3MBTL1GLAPTGDR2ALDH1A1HCRTR1 | |
| SCHEMBL30772315 | 0.75 | HSP90AA1 (0.48) | L3MBTL1ALDH1A1CYP2C19HPGDMAPT | |
| SCHEMBL5814653 | 0.75 | FFAR1 (0.53) | L3MBTL1CYP2C19MAPTTDP1NPSR1 | |
| SCHEMBL28097871 | 0.75 | FFAR1 (0.37) | L3MBTL1GLAALDH1A1GAACYP2C19 | |
| SCHEMBL2747002 | 0.75 | CYSLTR2 (0.39) | L3MBTL1CYP2C19MAPTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392398-B2 | Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2018-02-22 | — | — | US | disclosed |
| US-9815845-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-11-14 | — | — | US | disclosed |
| US-9802948-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERISTY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170107227-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-04-20 | — | — | US | disclosed |
| US-9597325-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170044175-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-02-16 | — | — | US | disclosed |
| US-9399644-B2 | [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer | TRUSTEES OF BOSTON UNIVERSITY (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150344491-A1 | [1,3] DIOXOLO [4,5-G] QUINOLINE-6(5H)THIONE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-12-03 | — | — | US | disclosed |
| US-9175001-B2 | [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140249312-A1 | [1,3]DIOXOLO[4,5-G]QUINOLINE-6(5H)THIONE AND [1,3]DIOXOLO[4,5-G][1,2,4]TRIAZOLO[1,5-A]QUINOLINE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | TRUSTEES OF BOSTON UNIVERSITY (US) | 2014-09-04 | — | — | US | disclosed |
| US-20130324570-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2013052465-A1 | [1,3]DIOXOLO[4,5-G]QUINOLINE-6(5H)THIONE AND [1,3]DIOXOLO[4,5-G][1,2,4]TRIAZOLO[1,5-A]QUINOLINE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2012050985-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249312-A1 | [1,3]DIOXOLO[4,5-G]QUINOLINE-6(5H)THIONE AND [1,3]DIOXOLO[4,5-G][1,2,4]TRIAZOLO[1,5-A]QUINOLINE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | GTF3C5, GTF3C2, GTF3C1 | L3MBTL1 316/4885GLA 515/4885PTGDR2 2892/4885 |
| US-20170107227-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF3C5 | L3MBTL1 1141/4885GLA 1016/4885PTGDR2 4618/4885 |
| US-20150344491-A1 | [1,3] DIOXOLO [4,5-G] QUINOLINE-6(5H)THIONE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER | GTF3C5, GTF2F1, GTF3C2 | L3MBTL1 323/4885GLA 456/4885PTGDR2 3267/4885 |
| US-20130324570-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF2F2 | L3MBTL1 1149/4885GLA 901/4885PTGDR2 4547/4885 |
| US-20170044175-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF3C5 | L3MBTL1 1141/4885GLA 1016/4885PTGDR2 4618/4885 |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF3C5 | L3MBTL1 1141/4885GLA 1016/4885PTGDR2 4618/4885 |
| US-10392398-B2 | Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics | GTF2F1, HDGF, GTF3C5 | L3MBTL1 1141/4885GLA 1016/4885PTGDR2 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.